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PCTAIRE-1 [also known as cyclin-dependent kinase 16
(CDK16)] is implicated in various physiological processes such as
neurite outgrowth and vesicle trafficking; however, its molecular
regulation and downstream targets are largely unknown. Cyclin Y
has recently been identified as a key interacting/activating cyclin
for PCTAIRE-1; however, the molecular mechanism by which
it activates PCTAIRE-1 is undefined. In the present study, we
initially performed protein sequence analysis and identified two
candidate phosphorylation sites (Ser12 and Ser336) on cyclin Y that
might be catalysed by PCTAIRE-1. Although in vitro peptide
analysis favoured Ser12 as the candidate phosphorylation site,
immunoblot analysis of cell lysates that had been transfected with
wild-type (WT) or kinase-inactive (KI) PCTAIRE-1 together
with WT or phospho-deficient mutants of cyclin Y suggested
Ser336, but not Ser12, as a PCTAIRE-1-dependent phosphorylation
site. Monitoring phosphorylation of Ser336 may provide a useful
read-out to assess cellular activity of PCTAIRE-1 in vivo;
however, a phospho-deficient S336A mutant displayed normal
interaction with PCTAIRE-1. Unbiased mass spectrometry
and targeted mutagenesis analysis of cyclin Y identified key
phosphorylation sites (Ser100 and Ser326) required for 14-3-3
binding. Recombinant WT cyclin Y, but not a S100A/S326A
mutant, prepared in COS-1 cells co-purified with 14-3-3 and
was able to activate bacterially expressed recombinant PCTAIRE-
1 in cell-free assays. Finally, we observed that recently identified
PCTAIRE-1 variants found in patients with intellectual disability
were unable to interact with cyclin Y, and were inactive enzymes.
Collectively, the present work has revealed a new mechanistic
insight into activation of PCTAIRE-1, which is mediated through
interaction with the phosphorylated form of cyclin Y in complex
with 14-3-3.
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INTRODUCTION
The human cyclin-dependent kinase 16 (CDK16) gene, which
encodes the protein kinase PCTAIRE-1 (also known as CDK16),
maps to the X chromosome (Xp11.3) whose defects and copy-
number variants have been linked to various diseases, including
intellectual disability and related disorders [1]. As a member of
the CDK family, early studies focused on the role of PCTAIRE-
1 in cell-cycle regulation. Although still controversial, there is
no established evidence that PCTAIRE-1 plays a critical role
in cell-cycle control [2–4]. PCTAIRE-1 is expressed in post-
mitotic cells and displays a wide tissue distribution with highest
abundance in brain and testis [5,6] and has been implicated
in diverse biological and physiological processes, including
neurite outgrowth [3,7], vesicle trafficking [8,9], spermatogenesis
[5], glucose homoeostasis [10,11] and, most recently, muscle
differentiation [12].
PCTAIRE-1 is one of three members of the PCTAIRE family
(namely PCTAIRE-1, -2 and -3). PCTAIRE is composed of
three principal domains: a central kinase domain that is highly
conserved between the three isoforms (∼80% protein sequence
identity), flanked by a long N-terminus and a short C-terminus of
which the extreme N-terminus is unique to each isoform [2,13].
Until recently, PCTAIRE and its closely related kinase PFTAIRE
(PFTAIRE-1/2, also known as CDK14/15) were considered
‘orphan CDKs’, because their putative cyclin partners were
unknown and thus termed according to a characteristic α-helical
sequence that corresponds to the ‘PSTAIRE’ helix in the cyclin-
binding domain of CDK1 or CDK2 [13]. However, recent studies
identified a key cyclin-binding partner, namely cyclin Y. The
original work implicating that cyclin Y might be a potential
partner for PCTAIRE-1 came from a large-scale yeast two-hybrid
screen in Drosophila melanogaster, where Eip63E (ecdysone-
induced protein encoded by a gene at chromosomal position 63E),
most similar to the mammalian PFTAIRE-1/CDK14, interacted
with a novel cyclin-like protein, coded as CG14939. Subsequent
studies confirmed interaction between Eip63E and CG14939
(renamed ‘cyclin Y’) in Drosophila cells [14] and between
human PFTAIRE-1 and cyclin Y [15]. Ou et al. [16] have
demonstrated that the Caenorhabditis elegans homologue of
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PCTAIRE-1, PCT1, bound to CYY1, the C. elegans homologue
of cyclin Y. Subsequently, Mikolcevic et al. [5] reported that
mammalian PCTAIRE-1 also interacts with cyclin Y, and we have
demonstrated that binding of PCTAIRE-1 to cyclin Y increases
(>100-fold) PCTAIRE-1 catalytic activity [6].
Although PCTAIRE-1 is implicated in a wide variety of
cellular and physiological processes, the molecular basis of its
regulation as well as downstream pathway(s) leading to
such physiological outcomes remains elusive. Since no bona
fide substrates for PCTAIRE-1 have been identified and the
phosphorylation consensus sequence had not been defined, we
recently performed positional scanning using a peptide library.
We identified that PCTAIRE-1 has a unique substrate preference
compared with other CDK members and developed a novel
peptide substrate termed ‘PCTAIRE-tide’ [6]. This enabled us
to more robustly and quantitatively measure PCTAIRE-1 activity
to study its molecular regulation.
In the present study, we initially undertook protein sequence
analysis of human cyclin Y and identified two conserved proline-
directed serine residues (Ser12 and Ser336) that resemble the
preferred consensus sequence for PCTAIRE-1. This led us
to hypothesize that PCTAIRE-1 phosphorylates cyclin Y and
that this phosphorylation may at least partly influence their
interaction and hence activity. We have identified Ser336 as
a PCTAIRE-1-dependent phosphorylation site, but found that
the phosphorylation of Ser336 has no significant impact on
interaction between PCTAIRE-1 and cyclin Y. Interestingly,
however, analysis of additional phosphorylation sites on cyclin
Y revealed that phosphorylation of Ser100 and Ser326 plays an
important role in binding and activating PCTAIRE-1 by promoting
binding to 14-3-3 proteins. We also report that recently identified
PCTAIRE-1 variants found in patients with intellectual disability
were unable to interact with cyclin Y and are inactive enzymes.
EXPERIMENTAL
Materials
Peptide substrates for kinase assays were synthesized by
GL Biochem. [γ -32P]ATP was from PerkinElmer. Horseradish
peroxidase (HRP)-conjugated secondary antibodies were from
Jackson Immuno Research. P81 paper was from Whatman.
All cell culture reagents were from Life Technologies. Unless
otherwise indicated all other reagents were from Sigma.
Antibodies
Anti-PCTAIRE-1 (C-16), anti-PCTAIRE-1 (G6.1) and anti-14-3-
3 (K-19) antibodies were from Santa Cruz Biotechnology. Anti-
cyclin Y antibody was from Proteintech. Anti-haemagglutinin
(HA) antibody was from Covance Research Products. The follow-
ing antibodies were raised in rabbit by YenZym Antibodies against
the indicated immunogens where denotes a phosphoamino acid:
pSer12-cyclin Y (YZ4631, VSSS*PKLRRNAHC-NH2), pSer100-
cyclin Y (YZ4891 second cycle, QIARKYSS*CSTIFLD-NH2),
pSer326-cyclin Y (YZ3909, RKRSAS*ADNLTLPC-NH2) and
pSer336-cyclin Y (YZ4633 second cycle, CDNLTLPRWS*PAIIS-
NH2). The following antibodies were raised in sheep by the
Division of Signal Transduction Therapy (University of Dundee)
against the indicated immunogens: GST (S902A, third bleed, GST
from Schistosoma japonicum), cyclin Y (S206D, third bleed, full-
length human GST–cyclin Y).
Cloning, mutagenesis and sequence analysis
All plasmid constructs were generated using standard molecular
biology techniques. The coding regions of PCTAIRE-1 isoform
1 (NM_006201.4) and 14-3-3ζ (NM_003406.3) were amplified
from human placental RNA, cyclin Y (NM_145012.4) from
testes RNA (Agilent Technologies) using Superscript III One
Step RT-PCR kit (Life Technologies). The resulting PCR
products were subcloned into an intermediate vector pJET
(Fermentas) or directly into the mammalian and bacterial
expression vectors, pCMV5 (AF239249.1) and pGEX-6P-1
(GE Healthcare). Site-directed mutagenesis was performed
using the QuikChange method (Agilent) using KOD Hot Start
DNA Polymerase (Novagen). The sequence of all constructs
was verified utilizing the BigDyeR Terminator 3.1 kit and
a 3500XL Genetic analyser (Life Technologies) in-house at
the Nestle´ Institute of Health Sciences. Sequence alignment
was performed using the Muscle algorithm, edited using the
Jalview alignment editor [17] and displayed using BOXSHADE
(http://www.ch.embnet.org/software/BOX_form.html).
Cell culture, transfection and harvesting
COS-1 cells (A.T.C.C.) were maintained in high-glucose
Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% (v/v) FBS under 5% CO2. Cells were transfected with
DNA using polyethyleneimine and harvested 36 h post-
transfection. Cells were washed with ice-cold PBS and scraped
into lysis buffer (50 mM Tris/HCl, pH 7.5, 1 mM EDTA, 1 mM
EGTA, 0.27 M sucrose, 1% (w/v) Triton X-100, 50 mM NaF,
5 mM Na4P2O7, 1 mM Na3VO4, 1 mM DTT, 1 mM benzamidine
and 0.5 mM PMSF). Lysates were clarified at 17000 g for
10 min at 4 ◦C and stored at − 80 ◦C. Protein concentration was
determined using Bradford reagent and BSA standard.
Mass spectrometry (MS) analysis of HA–cyclin Y
COS-1 cells were transfected with HA-tagged human cyclin Y
with or without co-transfection with FLAG–PCTAIRE-1 and
lysates were prepared 36 h later as described above. HA–cyclin Y
was immunoprecipitated from 2 mg of lysate using HA–agarose,
washed twice with 0.5 ml of lysis buffer plus 0.5 M NaCl, twice
with 0.5 ml of buffer A (50 mM Tris/HCl, pH 8, 0.1 mM EGTA
and 1 mM DTT) and eluted with Laemmli sample buffer. Eluted
HA–cyclin Y was separated by SDS/PAGE and stained with
colloidal Coomassie (Blue Life Technologies). The HA–cyclin
Y band was excised, destained, in-gel reduced and alkylated
with iodoacetamide (50 mM), then dried with acetonitrile
followed by Speed Vac concentration. Samples were digested
with 60 μl of 2 μg/ml trypsin (sequencing grade, Promega) in
50 mM triethylammonium bicarbonate (TEAB), pH 8, overnight.
Peptides were extracted with an equal volume of acetonitrile,
dried and redissolved in 60 μl of 5% acetonitrile/10 mM TEAB.
Samples were analysed by LC–MS on a 180 mm × 0.075 mm
packed emitter (Reprosil C18 3 μM) coupled to an Orbitrap Velos
MS system. After trapping the peptides on a 20 mm × 0.1 mm
C18 trap column (Nanoseparations) equilibrated in buffer A (2%
acetonitrile/0.1% formic acid in water) at 7 ml/min, peptides
were separated using a discontinuous gradient from 98% buffer
A:2% buffer B (80% acetonitrile/20% water/0.1% formic
acid) to 80% buffer B over 60 min at 300nl/min. The ten
most abundant precursors detected in the Orbitrap at 30000
resolution (2–4+ charge state) were selected for MS/MS in
the LTQ Velos. To ensure the best fragmentation spectrum
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for any phosphopeptide was obtained, the precursors were
fragmented using multistage activation (MSA) of the precursor
mass (m/z) minus 49, 32.33 and 24.25 Da (this represents the
loss of H3PO4 from a 2+, 3+ or 4+ precursor ion). Raw files
were processed using Proteome Discoverer 1.4 and searched
using Mascot 2.3 against the Swiss Prot database (human
only), allowing for carbamidomethyl modification of cysteine,
oxidation of methionine and phosphorylation of serine/threonine/
tyrosine.
Preparation of GST-tagged proteins in Escherichia coli
GST-tagged human PCTAIRE-1, human cyclin Y and human
14-3-3ζ in pGEX-6P were expressed in Escherichia coli BL21-
CodonPlus(DE3)RIL cells and isolated by column purification
using glutathione–Sepharose 4B. Briefly, transformed E. coli cells
were cultured in LB medium until a OD600 of 0.6 was attained and
induced with 0.2 mM IPTG for 16 h at 18 ◦C. Cells were pelleted
by centrifugation at 5000 g for 30 min, lysed in 50 mM Tris/HCl,
pH 7.5, 0.25 M NaCl, 0.1 mM EDTA, 1 mM benzamidine/HCl
and 1 mM DTT by sonication and clarified by centrifugation
at 30000 g for 30 min. Supernatants were incubated with
glutathione–Sepharose 4B for 1 h at 4 ◦C, washed extensively
with lysis buffer and eluted with 20 mM reduced glutathione
in 50 mM Tris/HCl, pH 8. Preparations were gel filtered over
Sephadex G-25 to remove excess glutathione and the GST-tag
was either retained or cleaved using human rhinovirus (HRV) 3C
protease. Protein concentration was estimated by densitometry
of Coomassie Blue-stained gels using BSA standards. Protein
preparations were snap-frozen in liquid nitrogen and stored at
− 80 ◦C in 50 mM Tris/HCl, pH7.5, 0.15 M NaCl, 0.1 mM EDTA
and 10% (v/v) glycerol.
Baculovirus protein expression and purification
N-terminal hexahistidine (His6)-tagged cyclin Y wild-type (WT)
and S326A constructs were used to generate recombinant
baculovirus using the Bac-to-Bac system (Life Technologies)
following the manufacturer’s protocol. Baculovirus protein
expression and purification was performed by the DSTT.
Spodoptera frugiperda Sf 21 cells (1.5 × 106/ml) were infected at
a multiplicity of infection of 5 and harvested 48 h post-infection.
His6-tagged proteins were affinity purified using Ni-NTA (Ni2+-
nitrilotriacetic acid)–agarose.
Preparation of tissue lysates
Animal studies were approved by the local Ethical Committee of
the Canton of Vaud, Switzerland, and performed under licence
number 2519. C57BL/6N mice were obtained from Charles River
Laboratories. Mice were killed by CO2 exposure and tissues
were rapidly dissected and frozen in liquid nitrogen. Tissues
were homogenized using a rotor-stator homogenizer (Polytron,
Kinematica AG) in lysis buffer, clarified at 17000 g for 10 min at
4 ◦C and stored at − 80 ◦C. Protein concentration was determined
using Bradford reagent and BSA as standard.
Immunoprecipitation
Tissue lysates were incubated with 1 μg of anti-cyclin Y S206D
antibody and 5 μl of Protein G–Sepharose for 1 h at 4 ◦C. FLAG-
and HA-tagged proteins were isolated from cells using 5 μl of
FLAG M2– or HA–agarose respectively. Immune complexes were
pelleted at 500 g for 1 min and washed twice with 0.1 ml of lysis
buffer plus 0.5 M NaCl, twice with 0.1 ml of buffer A and eluted
with Laemmli sample buffer for analysis by immunoblotting or
assayed directly for kinase activity.
Immunoblotting
Cell/tissue lysates were denatured in Laemmli buffer, separated by
Tris/glycine SDS/PAGE and transferred onto PVDF a membrane.
Membranes were blocked for 1 h at room temperature in 20 mM
Tris/HCl (pH 7.6), 137 mM NaCl, 0.1% (v/v) Tween 20 (Tris
buffered saline with Tween-20; TBST) containing 5% (w/v)
skimmed milk. Membranes were incubated in primary antibody
prepared in TBST containing 5% (w/v) BSA overnight at 4 ◦C.
Signal detection was performed using HRP-conjugated secondary
antibodies and enhanced chemiluminescent reagent.
Kinase assay
Purified recombinant PCTAIRE-1 or immune complexes isolated
from cell/tissue lysates were assayed for phosphotransferase
activity in a final assay volume of 50 μl containing 50 mM
HEPES, pH 7.5, 0.1 mM EGTA, 10 mM magnesium acetate,
0.1 mM [γ -32P]ATP (300 c.p.m./pmol), 1 mM DTT and 50 μM
PCTAIRE-tide (PKSPKARKKL) or the indicated concentrations
of peptide substrate. Reactions were incubated at 30 ◦C and
terminated by spotting onto P81 paper and immersion in 75 mM
H3PO4. P81 filters were washed three times for 10 min with
H3PO4, rinsed with acetone, air-dried and incorporation of
γ -32P determined by Cherenkov counting. Results are expressed
in units·mg− 1, where 1 unit is defined as the incorporation of 1
nmol of phosphate·min− 1.
14-3-3 binding/competition assay
FLAG–cyclin Y was immunoprecipitated from 50 μg of COS-1
lysates and washed as described above, then incubated for 20 min
at room temperature with 1 mM 14-3-3-binding phosphopeptide
(ARAAS*APA peptide, where S* denotes phosphoserine) in TBS
(50 mM Tris, 150 mM NaCl, 1 mM benzamidine/HCl, 1 mM
DTT and 0.03% Briji35). Non-phosphopeptide (ARAASAPA)
was used as negative control. After washing with ice-cold TBS,
0.1 μg of recombinant PCTAIRE-1 and/or 0.5 μg 14-3-3ζ (both
from E. coli) were added together or in isolation and incubated
for a further 20 min in TBS at room temperature. The immune
complexes were then washed and eluted with Laemmli sample
buffer for analysis by immunoblotting.
RESULTS
Sequence and peptide analysis identified potential PCTAIRE-1
phosphorylation sites on cyclin Y
Our recent positional scanning peptide library analysis has
revealed key substrate-specificity requirements of PCTAIRE-
1 [6]. We found that although an absolute requirement for a
proline residue immediately C-terminal to the phospho-acceptor
site ( + 1) and preference for a basic residue at + 2 are similar
to other conventional CDKs, some elements (preference for a
basic residue at + 4, but not at + 3) were unique to PCTAIRE-1.
We established a preferred consensus sequence of S-P-K/R-φ-
K/R/H (φ, represents a small aliphatic amino acid) and generated
an optimal substrate peptide (PCTAIRE-tide, PKSPKARKKL)
for robust measurements of recombinant and endogenous
c© 2015 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution License 3.0.
412 S.N. Shehata and others
Figure 1 Analysis of S-P motifs on human cyclin Y
(A) Diagram illustrating the domain organization of human cyclin Y with a global multiple sequence alignment of amino acid sequences surrounding the S-P motifs. Uni Prot accession numbers
are indicated in parentheses. (B) The in vitro phosphotransferase activity of FLAG–PCTAIRE-1–HA–cyclin Y complex was determined using peptides derived from residues surrounding Ser12 and
Ser336 on human cyclin Y, as well as a derivative of the Ser336 peptide based on the PCTAIRE-tide sequence (changes underlined). Peptide concentration was varied over the range 0–100 μM and
substrate saturation curves were fitted using non-linear regression to the Michaelis–Menten model. Fitted parameters [K m (μM) and V max (units·mg− 1)] are listed in the adjoining table. Results are
expressed as means +− S.D. and are representative of three independent experiments.
PCTAIRE-1 kinase activity in vitro [6]. Analysis of the protein
sequence of human cyclin Y, a cognate binding partner of
PCTAIRE-1 necessary for its activation [5,6], identified two
proline-directed serine residues (S-P motif; Figure 1A). One
of the S-P motifs (containing Ser336 in the human sequence)
is well conserved among mammals but not in lower organisms
such as D. melanogaster and C. elegans, whereas the other
S-P motif (containing Ser12) is conserved in humans and mouse,
as well as the majority of the lower organisms inspected.
We noted that residues surrounding Ser12 (SPKLRRN) of
human cyclin Y resemble the preferred consensus sequence for
PCTAIRE-1 (Figure 1A). Thus we hypothesized that PCTAIRE-1
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phosphorylates cyclin Y and that this modification influences
their interaction and hence catalytic activity of PCTAIRE-1. To
test this hypothesis, we initially generated synthetic peptides
encompassing residues surrounding Ser12 (termed Ser12-tide) and
Ser336 (plus an additional two arginine residues to enable efficient
binding of the peptide to P81 paper; termed Ser336-tide) of
human cyclin Y and determined in vitro substrate kinetics using
recombinant PCTAIRE-1–cyclin Y complex isolated from COS-
1 cells. Ser12-tide demonstrated a comparable Km to that of
PCTAIRE-tide (6.2 μM compared with 7.6 μM), but displayed
an approximately 4-fold lower Vmax (Figure 1B). In contrast, no
detectable activity above background was observed for Ser336-
tide, possibly due to absence of a preferred basic residue at
+ 2. In support of this, alteration of + 2 (alanine) and + 4
(isoleucine) amino acids to lysine and arginine respectively in
Ser336-tide to more resemble PCTAIRE-tide robustly increased
PCTAIRE-1 activity. However, the Km of the modified Ser336-
tide was still 10-fold higher than that of Ser12- or PCTAIRE-tide
(Figure 1B). Taken together, in vitro peptide analysis suggests
that Ser12, but not Ser336, is potentially a candidate for PCTAIRE-
1-targeted phosphorylation.
Detection and validation of PCTAIRE-1-dependent phosphorylation
of cyclin Y
To validate in vitro results obtained using short synthetic
peptides (Figure 1) and further explore whether the two potential
PCTAIRE-1 phosphorylation sites on full-length cyclin Y (Ser12
and Ser336) are phosphorylated in intact cells/tissues, we first
immunoprecipitated endogenous cyclin Y from mouse brain
extracts and immunoblotted with phospho-specific cyclin Y
antibodies. As illustrated in Figure 2(A), we could detect
phosphorylation of both Ser12 and Ser336 in these extracts.
To examine whether phosphorylation of either site influences
the cyclin Y interaction with/activation of PCTAIRE-1, we
ectopically co-expressed FLAG–WT PCTAIRE-1 and HA–WT
cyclin Y or phospho-deficient alanine mutants (S12A or S336A)
in COS-1 cells. We detected phosphorylation of both Ser12 and
Ser336 in WT cyclin Y bound to PCTAIRE-1 and observed that
the single phospho-deficient mutants could still interact with
and activate PCTAIRE-1 (Figure 2B). A modest reduction in
PCTAIRE-1 activity in the alanine mutants compared with WT
was observed, which could be due to slightly lower expression
of the mutants (Figure 2B). It can also be noted that the double
S12A/S336A mutant bound and activated PCTAIRE-1 similarly
to the WT and single mutants (results not shown). Interestingly,
but contrary to the results obtained using synthetic peptides in
the cell-free assay (Figure 1B), we found that whereas Ser12
phosphorylation can be detected irrespective of the presence of
PCTAIRE-1, Ser336 phosphorylation could only be observed when
PCTAIRE-1 was co-expressed (Figure 2C). We confirmed that
PCTAIRE-1-dependent phosphorylation of Ser336 requires intact
catalytic activity, as a catalytically inactive (D304A) mutant of
PCTAIRE-1 (which retains the ability to bind cyclin Y) abolished
Ser336 phosphorylation (Figure 2D). This is consistent with a
recent study reporting that PCTAIRE-1 phosphorylates Ser336 on
cyclin Y in cell-free assays, although the result was not shown
[5]. To further demonstrate that interaction of PCTAIRE-1 with
cyclin Y is critical for Ser336 phosphorylation, we overexpressed a
cyclin Y mutant (K225A) that cannot bind to PCTAIRE-1 [6].
Although Ser12 phosphorylation was detectable in the mutant
cyclin Y (albeit to a lesser degree compared with WT cyclin
Y, presumably due to lower expression), Ser336 could be seen
in WT cyclin Y when co-expressed with PCTAIRE-1, but not in
the K225A mutant (Figure 2E). Taken together, whereas in vitro
peptide analysis favoured Ser12 over Ser336 as PCTAIRE-1 targeted
phosphorylation site (Figure 1B), cellular experiments using full-
length recombinant cyclin Y have revealed Ser336 as a PCTAIRE-
1-dependent phosphorylation site.
Phospho-peptide mapping identified multiple phosphorylation
sites on cyclin Y
To determine whether there were other phosphorylation sites on
cyclin Y that are important for interaction with/activation of
PCTAIRE-1, we performed phosphopeptide mapping of cyclin
Y. Human HA–WT cyclin Y was transfected alone or with
human FLAG–WT PCTAIRE-1 or kinase-inactive (KI) FLAG–
PCTAIRE-1 (D304A) in COS-1 cells. HA–cyclin Y proteins
were affinity-purified, separated by SDS/PAGE (Figure 3A)
and in-gel digested with trypsin. The resulting peptides were
analysed by LC–MS/MS. The peptide sequence coverage was
69–81% (technical and biological replicates). We identified
several phosphopeptides in the LC–MS analysis and the sites
of phosphorylation were identified as listed in Figure 3B.
We observed that abundance of phosphopeptides containing
Ser336 was over 10-fold higher in cells with WT PCTAIRE-
1 overexpression compared with those from cyclin Y alone or
with KI (D304A) PCTAIRE-1 overexpression (Supplementary
Figure S1), which is consistent with the results described
above (Figures 2C and 2D) that Ser336 phosphorylation is
increased in a PCTAIRE-1-dependent mechanism. This pattern
was not observed for any of the remaining phosphopeptides
(Supplementary Figure S1).
Mutagenesis analysis revealed two key phosphorylation sites on
cyclin Y required for binding and activating PCTAIRE-1
We next sought to determine whether any of the newly
identified phosphorylation sites have key role(s) for interaction
and activation of PCTAIRE-1. For this purpose, we generated
a series of phospho-deficient mutants of human HA–cyclin
Y and co-transfected each mutant together with FLAG–WT
PCTAIRE-1 in COS-1 cells. Strikingly, we found that two point
mutants, S100A and S326A, were totally incapable of binding and
activating PCTAIRE-1, whereas other mutants show either full or
partial binding/activation capacity (Figure 4A). Protein sequence
alignment revealed that Ser100 and Ser326 are well conserved across
species (Figure 3C). Phosphorylation motif analysis of human
cyclin Y by Scansite [18] (http://scansite.mit.edu/) revealed
a relatively high probability that these sites mediate 14-3-3
binding. Therefore, we immunoblotted anti-FLAG (PCTAIRE-
1) immunoprecipitates with a anti-pan-14-3-3 antibody and
observed that there was an association between the amount
of cyclin Y bound to PCTAIRE-1 and 14-3-3 content in the
FLAG immunoprecipitates (Figure 4A). To confirm whether
Ser100 and Ser326 sites are phosphorylated in intact cells by an
alternative method (i.e. immunoblot with phosphorylation site-
specific antibodies) and if so, whether their levels are modulated
by the presence of PCTAIRE-1, we transfected WT or mutant
cyclin Y (S100A and S326A) with or without co-expression of
WT PCTAIRE-1. We observed that both Ser100 and Ser326 in WT
cyclin Y are phosphorylated to a similar extent in the presence or
absence of PCTAIRE-1 co-expression, as judged using phospho-
site-specific antibodies (Figure 4B). Interestingly, we observed
that phosphorylation of Ser100 was abolished in the S326A mutant,
whereas Ser326 phosphorylation was only modestly reduced in
the S100A mutant. This indicates that phosphorylation of Ser326
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Figure 2 Ser336 cyclin Y phosphorylation is PCTAIRE-1-dependent
(A) Endogenous cyclin Y was immunoprecipitated (IP) from 0.1 mg of brain homogenates of two C57BL/6N mice using anti-cyclin Y antibody and immunoblotted (IB) using the indicated antibodies.
(B) WT or serine-to-alanine mutants of the HA–cyclin Y S-P motifs were co-transfected with FLAG–PCTAIRE-1 in COS-1 cells. Lysates were immunoprecipitated using FLAG–agarose and either
immunoblotted with the indicated antibodies or assayed for PCTAIRE-1 kinase activity. (C) WT or serine-to-alanine (single or double) mutants of the HA–cyclin Y S-P motifs were transfected
in COS-1 cells with or without FLAG–PCTAIRE-1 and total lysates immunoblotted using the indicated antibodies. (D) HA–WT cyclin Y was expressed in COS-1 cells with or without FLAG WT
PCTAIRE-1 or kinase inactive (D304A) mutant and total lysates immunoblotted with the indicated antibodies. Alternatively, lysates were immunoprecipitated using FLAG– or HA–agarose followed
by immunoblotting. (E) HA–WT cyclin Y or K225A (binding-deficient mutant) were transfected in COS-1 cells with or without FLAG–WT PCTAIRE-1 or KI (D304A) mutant and total lysates were
immunoblotted using the indicated antibodies. Results are expressed as means +− S.D. and are representative of three independent experiments.
may be a prerequisite for Ser100 phosphorylation. Given that both
Ser100 and Ser326 are conserved between human cyclin Y and
cyclin Y-like-1 proteins (Figure 4C), we examined whether cyclin
Y-like-1 activates PCTAIRE-1 through binding that requires
phosphorylation of Ser122 and Ser344 (equivalent to Ser100 and Ser326
of human cyclin Y respectively). We found that cyclin Y-like-1
bound and activated PCTAIRE-1, which was abolished in the
S122A or S344A mutant (Figure 4C). We also found that 14-3-3
was only identified in PCTAIRE-1 complexed with WT cyclin
Y-like-1, but not the S122A or S344A mutant. To further examine
phosphorylation-dependent binding of 14-3-3 to cyclin Y, we
expressed WT or S326A human His6–cyclin Y in insect Sf21 cells
and affinity-purified recombinant cyclin Y proteins (Figure 4D).
We detected similar levels of Ser100 and Ser326 phosphorylation of
His6–WT cyclin Y compared with COS-1-derived HA–WT cyclin
Y, whereas phosphorylation of Ser100/Ser326 was not detectable
in the His6–S326A cyclin Y mutant. Immunoblotting of the
purified His6-cyclin Y detected 14-3-3 proteins in WT, but not
in the S326A mutant, even though the amount was much lower
(≈100-fold less) than that detected from COS-1 derived HA–
WT cyclin Y (Figure 4D). Finally, we immunoprecipitated
endogenous cyclin Y from mouse brain lysates and detected
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Figure 3 Mass spectrometry (MS)-based mapping of phospho-sites on human cyclin Y
(A) HA–cyclin Y expressed in COS-1 cells with or without FLAG–WT PCTAIRE-1 or KI (D304A) mutant was immunoprecipitated (IP) using HA–agarose and separated by SDS/PAGE. The gel was
stained with colloidal Coomassie. Rectangular boxes indicate where gel pieces were excised and analysed by MS. (B) Sequences and m/z scores of peptides identified during MS analysis of samples
excised in (A) that correspond to phosphorylation sites on human cyclin Y. (C) Global multiple sequence alignment of human cyclin Y with the indicated orthologues showing amino acid sequences
surrounding Ser100 and Ser326. MS experiments were repeated three times.
phosphorylation of Ser100 and Ser326, as well as 14-3-3 and
PCTAIRE-1 as binding proteins (Figure 4E). To further explore
the molecular mechanism underlining the interaction between
PCTAIRE-1 and cyclin Y, we generated a series of truncation and
alanine mutants of cyclin Y and co-expressed each mutant with
WT PCTAIRE-1 in COS-1 cells (Supplementary Figure S2A).
We observed that truncation mutants lacking up to 40 N-terminal
residues were still capable of binding to PCTAIRE-1 and also
14-3-3. Interestingly, however, mutants lacking the N-terminal
45 residues could no longer bind to PCTAIRE-1 or to 14-3-
3. To identify the key binding region/residue(s), we generated
additional mutants, particularly focusing on residues ranging from
41 to 45 of cyclin Y. We found that 41–45 cyclin Y mutant lost
binding to both PCTAIRE-1 and 14-3-3, and alanine scanning
revealed that point mutants H43A and I44A abolished binding to
PCTAIRE-1 and 14-3-3 (Supplementary Figure S2B). Although
this indicates that residues of the 41–45 region (particularly His43
and Ile44) play a key role in the binding of cyclin Y to PCTAIRE-1
that involves 14-3-3 binding, we cannot rule out the possibility
that truncation or mutation (i.e. alanine substitution) may have
disrupted normal protein folding of cyclin Y, although 14-3-3
binding is retained (although to a lower extent). To clarify this, it
will be necessary to obtain structural insights (e.g. crystal structure
of PCTAIRE-1–cyclin Y–14-3-3 complex).
Activation of bacterially expressed PCTAIRE-1 requires binding of
cyclin Y in association with 14-3-3
It has been reported that bacterially expressed PCTAIRE-1
(bPCTAIRE-1) is catalytically inactive [3]. In addition, we have
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Figure 4 Phosphorylation of Ser100 and Ser326 on cyclin Y are essential for binding PCTAIRE-1 and 14-3-3
(A) Serine-to-alanine phospho-mutants of cyclin Y sites identified by MS (Figure 3) were co-expressed with FLAG–WT PCTAIRE-1 in COS-1 cells and total lysates were immunoblotted (IB) using the
indicated antibodies. Additionally, lysates were immunoprecipitated (IP) using either FLAG– or HA–agarose and either immunoblotted or the FLAG-immunoprecipitates assayed for PCTAIRE-1 kinase
activity. (B) HA–WT cyclin Y or S100A and S326A mutants were expressed in COS-1 cells with or without FLAG–WT PCTAIRE-1 and lysates were immunoblotted using the indicated antibodies.
(C) HA–WT cyclin Y-like-1 or S122A and S344A mutants (corresponding to Ser100 and Ser326 in human cyclin Y respectively), were co-expressed with FLAG–WT PCTAIRE-1 in COS-1 cells and
total lysates were immunoblotted using the indicated antibodies. Lysates were further immunoprecipitated using FLAG–agarose and either immunoblotted or assayed for PCTAIRE-1 kinase activity.
Shown below is a global pairwise alignment of human cyclin Y and cyclin Y-like-1 showing amino acid sequences surrounding Ser100 and Ser326. (D) Immunoblot using the indicated antibodies of
defined amounts of purified human cyclin Y (WT or S326A) expressed and purified either in COS-1 cells (FLAG-tagged) or Sf21 cells (His6-tagged). Results are expressed as means +− S.D. and are
representative of three independent experiments. (E) Mouse brain lysates (0.1–1 mg) were immunoprecipitated using anti-cyclin Y antibody and the immunoprecipitates were immunoblotted with
the indicated antibodies. Results are representative of three independent experiments (n=4).
observed that co-incubation with bacterially expressed cyclin
Y does not activate bPCTAIRE-1 in a cell-free assay (results
not shown). This is unsurprising considering that our results
suggest an absolute requirement for cyclin Y phosphorylation
(and potentially 14-3-3 binding) for efficient binding/activation
of PCTAIRE-1. This suggests that bPCTAIRE-1 may be activated
by the cyclin Y–14-3-3 complex isolated from eukaryotic cells.
We therefore incubated bPCTAIRE-1 with or without COS-
1 lysates ectopically expressing WT or phospho-deficient/14-
3-3-binding-deficient mutants (S100A or S326A) of cyclin
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Figure 5 Activation of bacterially expressed PCTAIRE-1 by mammalian cyclin Y in complex with 14-3-3
(A) PCTAIRE-1 (100 ng), expressed and purified from E. coli, was incubated with COS-1 lysates (200 μg) ectopically expressing the indicated HA–cyclin Y constructs and immunoprecipitated
(IP) using anti-PCTAIRE-1 (G6.1) antibody. Then, 30 % of the immunoprecipitated material was immunoblotted (IB) using the indicated antibodies and 10 % was assayed for kinase activity. (B) E.
coli-purified PCTAIRE-1 (1 μg) was incubated with 0.5 μg of Sf21-purified His–WT cyclin Y or S326A mutant and with 1 μg of E. coli-purified 14-3-3ζ , together or in isolation and assayed for
kinase activity. (C) A 100 ng amount of each of four E. coli-purified GST–PCTAIRE-1 proteins [WT (full-length), 106–476 truncation, kinase-domain (165–446) and KI (D304A) mutant] were incubated
with 0.25 μg of COS-1-purified FLAG–cyclin Y and assayed for kinase activity. Immunoblotting was performed using GST-tagged PCTAIRE-1 proteins and activity assay was performed using
GST-cleaved PCTAIRE-1 proteins. (D) FLAG–cyclin Y was immunoprecipitated from 50 μg of transfected COS-1 lysates using FLAG–agarose and incubated with 1 mM ARAAS*APA/14-3-3-binding
phosphopeptide (* indicates phosphoserine) for 20 min at room temperature. Non-phosphopeptide ARAASAPA was used as a negative control. After washing, 100 ng of PCTAIRE-1 and 0.5 μg of
14-3-3ζ (both expressed and purified from E. coli), were then added together or in isolation and incubated with the immunoprecipitated protein for a further 20 min at room temperature. Samples
were washed and 30 % was immunoblotted using the indicated antibodies and 20 % was assayed for PCTAIRE-1 kinase activity. Results are expressed as means+− S.D. and are representative of
three independent experiments.
Y, immunoprecipitated using anti-PCTAIRE-1 antibody and
assessed binding and kinase activity (Figure 5A). As expected,
bPCTAIRE-1 on its own was inactive. In contrast, WT cyclin Y
(in complex with 14-3-3), but not S100A or S326A, bound and
robustly activated bPCTAIRE-1. To rule out the possibility that
the observed activity was due to the presence of a contaminating
kinase in the purified HA–WT cyclin Y preparation, we also
incubated the WT cyclin Y with KI (D304A) bPCTAIRE-1. This
confirmed that the observed activity is intrinsic to bPCTAIRE-
1. We also performed a similar experiment using Sf21-derived
cyclin Y preparations (Figure 4D) and again observed that
WT, but not S326A, activated bPCTAIRE-1 but only in the
presence of additional recombinant 14-3-3 (of low abundance
in Sf21-derived cyclin Y) suggesting that the formation of a
ternary complex of PCTAIRE-1–cyclin-Y–14-3-3 is essential
for kinase activity (Figure 5B). In line with a previous report
(using a preparation of PCTAIRE-1 from mammalian cells)
[5], partially truncated forms (1–105 and 477–496/106–476),
but not the kinase domain fragment (165–446) of bPCTAIRE-
1, could be activated when co-incubated with COS-1 cell-
derived WT cyclin Y preparation (Figure 5C), indicating the
importance/requirement of regions N- and C-terminal to/flanking
the kinase domain for cyclin Y-mediated PCTAIRE-1 activation.
To further demonstrate that 14-3-3 is necessary for cyclin
Y binding and activation of bPCTAIRE-1, we measured cyclin Y
binding and activation of bPCTAIRE-1 after addition of the
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14-3-3-binding phosphopeptide ARAAS*APA (where S* denotes
phosphoserine). Non-phosphopeptide (ARAASAPA) was used
as a negative control (Figure 5D). FLAG–WT cyclin Y was
immunoprecipitated from COS-1 cells followed by incubation
with the 14-3-3-binding phosphopeptide/ARAAS*APA. After
washing of unbound/dissociated proteins, along with excess
phosphopeptide, bPCTAIRE-1 and 14-3-3 were added/incubated
together or in isolation with the immunoprecipitate, washed and
then analysed by immunoblotting and kinase activity assay. We
observed that the 14-3-3-binding phosphopeptide/ARAAS*APA
severely diminished cyclin Y interaction with bPCTAIRE-1
and abolished bPCTAIRE-1 activity, which was restored when
14-3-3 proteins were exogenously added. In contrast, control
peptide (non-phosphopeptide/ARAASAPA) did not affect cyclin
Y binding to bPCTAIRE-1 or the consequent bPCTAIRE-1
activation.
Likely disease-associated variants of CDK16/PCTAIRE-1 cause
loss-of function
X-linked intellectual disability (XLID) is a clinically and
genetically heterogeneous disorder with >100 genes identified
so far. For some of these XLID genes, only very few
families with pathogenic variants have so far been reported,
suggesting that mutations in these genes are very rare. In
our recent study of 405 families with XLID investigated by
X chromosome exome sequencing, we identified a variant
in CDK16/PCTAIRE-1 in a family with four affected males
who all carry the variant and their mothers are heterozygous
carriers [chrX:47086041-47086043, delTG, Q00536-2 (isoform
2): p.Trp400ValfsVPAP]. This result led us to propose that
CDK16/PCTAIRE-1 is a novel candidate XLID gene [19].
An additional protein truncating CDK16/PCTAIRE-1 variant,
classified as pathogenic or probably pathogenic (probably
affecting function) has been identified in an unrelated clinical
case [chrX:47086497C>T, Q00536-2 (isoform 2): p.Arg488Ter]
(http://genetics.emory.edu/egl/emvclass/emvclass.php and Clin-
Var database (http://www.ncbi.nlm.nih.gov/clinvar/variation/
166819/). Thus we investigated whether these variants could have
an effect on cyclin Y–14-3-3 binding and also on PCTAIRE-1
enzymatic activity. For this purpose, we ectopically expressed
both variants of human PCTAIRE-1 (FLAG–PCTAIRE-1
Trp400ValfsVPAP and FLAG–PCTAIRE-1 Arg488Ter) and its
reference WT (isoform 2) together with WT cyclin Y (Figures 6A
and 6B). Isoform 2 has a 74 amino acid extension at its N-terminus
compared with isoform 1 [which has been used throughout
the present study (except studies shown in Figure 6) and by
others]. PCTAIRE-1 isoform 2 showed modestly lower expression
compared with isoform 1, but displayed relatively comparable
binding to cyclin Y–14-3-3 as well as activity to that of isoform
1. We observed both pathogenic variants consistently expressed
much lower than their reference WT isoform 2 (Figure 6B),
suggesting that they may be less stable than WT PCTAIRE-1
isoform 1. The variants were catalytically inactive {although they
still contain key features of a functional kinase such as the VALK,
HRD and HFD motifs [20] (Figure 6A)} and they displayed no or
marginally detectable binding to cyclin Y, even when the amount
of loading was matched to that of WT (isoform 2) (Figure 6B;
Supplementary Figure S3).
DISCUSSION
Several studies, including our own, have recently established that
activation of PCTAIRE-1/CDK16 requires binding of cyclin Y
[5,6,13,16]; however, the underlying molecular mechanism that
mediates this interaction was elusive. We demonstrate in the
present study that phosphorylation of cyclin Y (Ser100 and/or
Ser326) and also cyclin Y-like-1 protein (Ser122 and/or Ser344,
equivalent to Ser100 and Ser326 of cyclin Y respectively) promotes
binding to 14-3-3 proteins in which both events are necessary for
binding to, and activation of, PCTAIRE-1.
Given that residues surrounding Ser12 and Ser336 comprise
the preferred consensus sequence for PCTAIRE-1, our initial
hypothesis was that PCTAIRE-1 phosphorylates cyclin Y and
that this modification influences their interaction. We identified
Ser336, but not Ser12, as a PCTAIRE-1-dependent phosphorylation
site; however, contrary to our hypothesis, phospho-deficient
S336A mutant displayed normal binding to PCTAIRE-1.
Although the functional role of Ser336 phosphorylation is still
unknown, monitoring the phosphorylation of Ser336 may be
a useful read-out to assess activity of PCTAIRE-1 in intact
cells/tissues in the absence of well-characterized downstream
substrates.
To our knowledge, the present study is the first study
demonstrating that the interaction between PCTAIRE-1 and
cyclin Y requires phosphorylation of cyclin Y that results in
14-3-3 binding. However, it should be noted that a recent
study by Li et al. [21] has reported cyclin Y binding of
14-3-3, which was associated with interaction with a closely
related kinase of PCTAIRE-1, namely PFTAIRE-1/CDK14. They
showed that the S100A/S326A double mutant of cyclin Y failed
to interact with 14-3-3 and PFTAIRE-1/CDK14. However, Li
et al. did not provide evidence that Ser100 and Ser326 were
indeed phosphorylated in cells. A follow-up study by the
same group claimed that they identified several phosphorylation
sites on cyclin Y using MS; however, they did not provide
data regarding the identity of specific phosphopeptides [22].
Surrounding sequences of the identified phosphopeptides (that
include Ser100 or Ser326) in the present study contain multiple
serine residues (Figure 3B). The phosphorylated residues
were confidently assigned from the MS/MS spectra using
bioinformatics tools, but we further validated the phosphorylation
of both sites using phospho-site-specific antibodies. Although
we observed that a single serine substitution by a non-
phosphorylatable alanine residue, S100A or S326A, was
sufficient to abolish 14-3-3 binding, the S326A mutation
resulted in ablation of Ser100 phosphorylation. This indicates
that phosphorylation of Ser326 may be a prerequisite event for
phosphorylation of Ser100 or alternatively the S326A mutation
prevented the upstream kinase(s) from phosphorylating the Ser100
residue. It is unclear therefore whether Ser100 phosphorylation
alone is sufficient for 14-3-3 binding or whether Ser326
phosphorylation also plays a role.
In cultured cell lines, PCTAIRE-1 is phosphorylated at several
residues, including Ser119 and Ser153. These sites have been shown
to be substrates for protein kinase A (PKA) in vitro [3] and
also in intact cells [5] in the case of Ser153. Phosphorylation
of Ser119 and Ser153 creates 14-3-3 consensus binding motifs,
whose binding activity has been confirmed by overexpression and
mutagenesis study [3]. However, the function of this modification
and 14-3-3 binding has not been resolved. Given that we were
able to activate bPCTAIRE-1 by co-incubating with COS-1-
derived/purified cyclin Y in complex with 14-3-3, it is unlikely that
direct binding of 14-3-3 to PCTAIRE-1 is an essential mechanism
by which PCTAIRE-1 is activated.
As part of systematic X-chromosome exome re-sequencing
of index patients from 405 families with XLID, a unique
CDK16/PCTAIRE-1 variant was identified in a multigenerational
family [19]. In addition, evidence from other studies suggests a
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Figure 6 Disease-associated human PCTAIRE-1 variants abolish cyclin Y binding and kinase activity
(A) Diagram showing relative start and end positions of human PCTAIRE-1 isoform 1 and 2 (Uni Prot accession numbers in parenthese) with respect to the kinase domain (area between vertical
dashed lines). Relative positions of motifs required for an active kinase (VALK, HRD and DFG motifs) are indicated by vertical unbroken lines pointing downwards. Disease-associated variants
in isoform 2 that lead to truncations are shown on the right. For both isoforms, amino acid residues of the kinase domain and total length are indicated by numbers. (B) Isoform 1 of FLAG–WT
PCTAIRE-1 or KI (D304A) mutant, and isoform 2 of FLAG–WT PCTAIRE-1 or disease-associated variants (R488Ter and W400VfsVPAP) were co-expressed with HA–WT cyclin Y in COS-1 cells and
total lysates were immunoblotted (IB) using the indicated antibodies. Lysates were immunoprecipitated (IP) using FLAG–agarose and either assayed for kinase activity or immunoblotted using the
indicated antibodies. Additional increased amounts of disease-associated variants assayed or immunoblotted after immunoprecipitation are also indicated. Results are expressed as mean +− S.D.
and are representative of three independent experiments.
role for PCTAIRE-1 in brain function. In more detail, in extreme
fatal primary human microcephaly, due to a deleterious variant in
megakaryoblastic leukemia 2 (MKL2) [23] and in MKL1/MKL2
double knockout mice with defective neuronal migration
and neurite outgrowth during brain development, PCTAIRE-
1 expression is decreased [7]. Also, targeted overexpression
of PCTAIRE-1 into rat hippocampus with virus-mediated gene
transfer caused memory deficits [24]. Combined with the results of
this study showing that patient-related truncated protein mutants
are unstable and catalytically inactive and therefore loss of
protein function mutations, these data suggest that PCTAIRE-
1 plays an important role for normal brain development and
function and hence its expression and activity need to be tightly
regulated.
In summary, our work has provided a key mechanistic insight
into the regulation/activation of PCTAIRE-1, which is mediated
through binding of phosphorylated cyclin Y in complex with 14-
3-3 protein. CDK16/PCTAIRE-1 has emerged as a potential key
player for normal brain development and function, but further
studies are required to identify downstream molecules/pathways
that link PCTAIRE-1 and biological/physiological processes in
brain.
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